Last reviewed · How we verify
NCT04530240
Equity and Efficacy of Allocation Priority for Liver Transplantation Patients With MELD≥30 in Italy
trial testing Liver Transplantation in Liver Transplant Disorder in 4,238 participants. Completed in 31 December 2019.
31 August 2018
Quick facts
| Lead sponsor | University of Bologna |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 4,238 |
| Start date | 1 August 2010 |
| Primary completion | 31 August 2018 |
| Estimated completion | 31 December 2019 |
Drugs / interventions tested
- Liver Transplantation
Conditions studied
- Liver Transplant Disorder — all drugs for Liver Transplant Disorder →
- HCC — all drugs for HCC →
Sponsor
University of Bologna
Who can join
Eligibility, any sex, with Liver Transplant Disorder or HCC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In Italy, since August 2014, liver transplantation (LT) candidates with MELD≥30 receive a priority allocation consenting them to access in an organ sharing macroarea. The primary intent of this policy is to minimize the higher risk of waiting list dropout observed in these patients. Another objective of this allocation strategy is to reduce the waiting time, thus performing the LT in better clinical conditions. This multicentre retrospective national study aims to evaluate several parameters of efficacy and equity, such as waiting time in the list, dropout rate, and graft survival, in two eras of enlisted patients, before and after the introduction of the macroarea sharing policy in Italy. With the intent to minimize the presence of possible selection biases, the two groups were matched trough Propensity Score Matching (PSM).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
Ravaioli M, Lai Q, Sessa M, Ghinolfi D, et al · · 2022 · cited 12× · PMID 34774638 · DOI 10.1016/j.jhep.2021.10.024
Verify or expand the search:
- PubMed search for NCT04530240
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Liver Transplantation
Trials testing the same drug.
- NCT05879328 — The ImmunoXXL Study · unknown
- NCT05289609 — Developing Prediction Models for Allograft Failure After Liver Transplantation · unknown
- NCT05087550 — Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation · completed
- NCT05185245 — Liver Transplantation for Non-Resectable Colorectal Liver Metastasis · NA · recruiting
- NCT04789213 — Mortality, Morbidity and Risk Factors of Liver Retransplantation · completed
Other recruiting trials for Liver Transplant Disorder
Currently open trials in the same condition.
- NCT07315204 — Viability Assessment Using FMN Measured in Perfusate and Bile During Normothermic Machine Perfusion · recruiting
- NCT06455280 — A Study of SIPLIZUMAB in AILD and LT Patients · Phase 1 · recruiting
- NCT06577480 — Validity and Reliability of the Turkish Version of the Post-Liver Transplant Quality of Life Questionnaire · active not recruiting
- NCT06563570 — The Effect of Teleyoga in Liver Transplant Patients · NA · active not recruiting
- NCT05537948 — Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients · Phase 4 · active not recruiting
Other University of Bologna trials
Trials by the same sponsor.
- NCT07431047 — Fast-Track Protocol for Endovascular Aneurysm Repair (EVAR) of Infrarenal Abdominal Aortic Aneurysms · not yet recruiting
- NCT07295197 — Oral Indicators for ED Screening · recruiting
- NCT07198789 — Randomized, Double-blind Crossover Trial Comparing Low-GI Functional vs. Standard Wholegrain Carbohydrates on Glycolipid · NA · not yet recruiting
- NCT07127796 — Non-inferiority RCT on Fish Waste-Derived vs. Synthetic Vitamin D Supplementation in Healthy Adults With Suboptimal Vita · NA · not yet recruiting
- NCT07041060 — Evaluation of the Efficacy and Safety of Eolo in Patients With NERD · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04530240 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Bologna
- Last refreshed: 28 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04530240.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing